The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Genetic Variability in CYP3A5 and its Possible Consequences
Abstract
The cytochrome P450 3A (CYP3A) subfamily members are the most abundant and important drug-metabolizing enzymes in humans, and wide interindividual variability in CYP3A expression and function is present. CYP3A4 alone cannot fully explain the observed constitutive variability because its genetic variants are relatively uncommon and have limited functional significance, whereas CYP3A5 expression in humans is highly variable and may be contributory. However, it is difficult to delineate the relative contribution of CYP3A4 and CYP3A5, and to differentiate their effects on drug metabolism as their protein structure, function and substrates are so similar. By contrast, molecular biology methods provide the ability to identify CYP3A4 and CYP3A5 genotypes with certainty. This review collates currently available data on CYP3A5 polymorphisms, provides information on the population frequency of each genetic variant in major ethnic groups, and describes in vitro and in vivo studies that have attempted to identify genotype-phenotype associations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greenlee, R. T., Murray, T., Bolden, S., & Wingo, P. A. (2000) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.50.1.7 · Cited by 3,850
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature
Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00002 · Cited by 2,945
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576
CYTOCHROME P-450 3A4: Regulation and Role in Drug Metabolism
Guengerich, F. P. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.1 · Cited by 1,267
The Importance of Race and Ethnic Background in Biomedical Research and Clinical Practice
Burchard, E. G., Ziv, E., Coyle, N., Gomez, S. L., Tang, H., Karter, A. J., Mountain, J. L., Pérez-Stable, E. J., Sheppard, D., & Risch, N. (2003) · New England Journal of Medicine · doi:10.1056/nejmsb025007 · Cited by 1,103
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., & Nebert, D. W. (2004) · Pharmacogenetics · doi:10.1097/00008571-200401000-00001 · Cited by 1,027
Genetic contribution to variable human CYP3A-mediated metabolism
Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00066-2 · Cited by 990
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 895
Wacher, V. J., Wu, C., & Benet, L. Z. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130302 · Cited by 857
Salt Sensitivity of Blood Pressure in Humans
Weinberger, M. H. (1996) · Hypertension · doi:10.1161/01.hyp.27.3.481 · Cited by 854
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Self-citationSummary of information on human CYP enzymes: human P450 metabolism data
Rendic, S. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001392 · Cited by 820
Hentze, M. W., & Kulozik, A. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80542-5 · Cited by 809
Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D., & Thummel, K. E. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37149-6 · Cited by 789
Human P-glycoprotein transports cyclosporin A and FK506.
Saeki, T., Ueda, K., Tanigawara, Y., Hori, R., & Komano, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53221-x · Cited by 684
The genetic determinants of the CYP3A5 polymorphism
Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.-Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00005 · Cited by 673
Hesselink, D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00168-1 · Cited by 655
Goodwin, B., Hodgson, E., & Liddle, C. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12400-5 · Cited by 646
Cooper, R. S., Kaufman, J. S., & Ward, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmsb022863 · Cited by 624
Use of race and ethnicity in biomedical publication
Kaplan, J. B. (2003) · JAMA · doi:10.1001/jama.289.20.2709 · Cited by 609
Molecular Basis of Ethnic Differences in Drug Disposition and Response
Xie, H.-G., Kim, R. B., Wood, A. J., & Stein, C. M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.815 · Cited by 600
Self-citationAn mRNA Surveillance Mechanism That Eliminates Transcripts Lacking Termination Codons
Frischmeyer, P. A., van Hoof, A., O'Donnell, K., Guerrerio, A. L., Parker, R., & Dietz, H. C. (2002) · Science · doi:10.1126/science.1067338 · Cited by 590
Kronbach, T., Fischer, V., & Meyer, U. A. (1988) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1988.87 · Cited by 533
Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.
Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F. J., & Meyer, U. A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09118-7 · Cited by 532
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C., & Watkins, P. B. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116064 · Cited by 528
Schuetz, E. G., Beck, W. T., & Schuetz, J. D. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08713-9 · Cited by 494
Aoyama, T., Yamano, S., Waxman, D. J., Lapenson, D. P., Meyer, U. A., Fischer, V, Tyndale, R., Inaba, T., Kalow, W., Gelboin, H. V., et al. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)81632-5 · Cited by 482
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.883 · Cited by 471
Amirimani, B., Walker, A. H., Weber, B. L., & Rebbeck, T. R. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.18.1588 · Cited by 465
Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein
Kirn, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., et al. (1999) · Pharmaceutical Research · doi:10.1023/a:1018877803319 · Cited by 454
Self-citationCo-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam Metabolism
Lin, Y. S., Dowling, A. L. S., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J., Schuetz, E. G., & Thummel, K. E. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.162 · Cited by 449
Haufroid, V., Mourad, M., Van Kerckhove, V., Wawrzyniak, J., De Meyer, M., Eddour, D. C., Malaise, J., Lison, D., Squifflet, J.-P., & Wallemacq, P. (2004) · Pharmacogenetics · doi:10.1097/00008571-200403000-00002 · Cited by 447
Özdemir, V., KALOW, W., Tang, B.-K., Paterson, A. D., Walker, S. E., Endrényi, L., & Kashuba, A. D. M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200007000-00001 · Cited by 440
The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4
Tirona, R. G., Lee, W., Leake, B. F., Lan, L.-B., Cline, C. B., Lamba, V., Parviz, F., Duncan, S. A., Inoue, Y., Gonzalez, F. J., et al. (2003) · Nature Medicine · doi:10.1038/nm815 · Cited by 440
Self-citationStudies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).
Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T., & Vandenbranden, M. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09441-6 · Cited by 402
Christopher Gorski, J., Hall, S. D., Jones, D. R., & VandenBranden, M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90543-6 · Cited by 395
Sattler, M., Guengerich, F. P., Yun, C. H., Christians, U., & Sewing, K. F. (1992) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08793-8 · Cited by 385
Substrates of human hepatic cytochrome P450 3A4
Li, A. (1995) · Toxicology · doi:10.1016/0300-483x(95)03155-9 · Cited by 367
CYP3A gene expression in human gut epithelium
Kolars, J. C., Lown, K. S., Schmiedlin-Ren, P., Ghosh, M., Fang, C., Wrighton, S. A., Merion, R. M., & Watkins, P. B. (1994) · Pharmacogenetics · doi:10.1097/00008571-199410000-00003 · Cited by 365
CYP2C9 allelic variants: ethnic distribution and functional significance
Xie, H.-G., Prasad, H. C., Kim, R. B., & Stein, C. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00076-5 · Cited by 338
Self-citationRegulation of CYP3A Gene Transcription by the Pregnane X Receptor
Goodwin, B., Redinbo, M. R., & Kliewer, S. A. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.111901.111051 · Cited by 327
Macphee, I. A. M., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L., & Holt, D. W. (2002) · Transplantation · doi:10.1097/00007890-200212150-00002 · Cited by 315
Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA
Koch, I., Weil, R., Wolbold, R., Brockmöller, J., Hustert, E., Burk, O., Nuessler, A., Neuhaus, P., Eichelbaum, M., Zanger, U., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1108 · Cited by 314
Spencer, C. M., Goa, K. L., & Gillis, J. C. (1997) · Drugs · doi:10.2165/00003495-199754060-00009 · Cited by 307
Rae, J. M., Johnson, M. D., Lippman, M. E., & Flockhart, D. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29202-8 · Cited by 306
Watkins, P. B., Wrighton, S. A., Barnett, J. L., Lown, K. S., Kunze, K. L., Thummel, K. E., & Kolars, J. C. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/n8xg-qs69 · Cited by 304
Dunn, C. J., Wagstaff, A. J., Perry, C. M., Plosker, G. L., & Goa, K. L. (2001) · Drugs · doi:10.2165/00003495-200161130-00006 · Cited by 276
Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver
Schuetz, J. D., Beach, D. L., & Guzelian, P. S. (1994) · Pharmacogenetics · doi:10.1097/00008571-199402000-00002 · Cited by 273
Goh, B.-C., Lee, S.-C., Wang, L.-Z., Fan, L., Guo, J.-Y., Lamba, J., Schuetz, E., Lim, R., Lim, H.-L., Ong, A.-B., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.025 · Cited by 270
Consensus Document: Therapeutic Monitoring of Tacrolimus (FK-506)
Jusko, W. J., Thomson, A. W., Fung, J. J., McMaster, P. D., Wong, S. H., Zylber‐Katz, E., Christians, U., Winkler, M., Fitzsimmons, W. E., Lieberman, R., et al. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199512000-00011 · Cited by 267
Backman, J. T., Kivistö, K. T., Olkkola, K. T., & Neuvonen, P. J. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050420 · Cited by 266
Schuetz, E. G., Schinkel, A. H., Relling, M. V., & Schuetz, J. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4001 · Cited by 266
Patki, K. C., von Moltke, L. L., & Greenblatt, D. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.938 · Cited by 263
Floyd, M. D., Gervasini, G., Masica, A. L., Mayo, G., George, A. L., Bhat, K., Kim, R. B., & Wilkinson, G. R. (2003) · Pharmacogenetics · doi:10.1097/00008571-200310000-00003 · Cited by 261
Self-citationWestlind-Johnsson, A., Malmebo, S., Johansson, A., Otter, C., Andersson, T. B., Johansson, I., Edwards, R. J., Boobis, A. R., & Ingelman-Sundberg, M. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.755 · Cited by 258
Transcriptional Regulation of the Human CYP3A4Gene by the Constitutive Androstane Receptor
Goodwin, B., Hodgson, E., D'Costa, D. J., Robertson, G. R., & Liddle, C. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.2.359 · Cited by 254
The role of individual human cytochrpmes P450 in drug metabolism and clinical response
Cholerton, S., Daly, A. K., & Idle, J. R. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90140-2 · Cited by 246
Wandel, C. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.108506 · Cited by 246
Ball, S. E., Scatina, J., Kao, J., Ferron, G. M., Fruncillo, R., Mayer, P., Weinryb, I., Guida, M., Hopkins, P. J., Warner, N., et al. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70037-8 · Cited by 233
Identification of a polymorphically expressed member of the human cytochrome P-450III family.
Wrighton, S. A., Ring, B. J., Watkins, P. B., & VandenBranden, M. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09114-x · Cited by 228
Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene
Gellner, K., Eiselt, R., Hustert, E., Arnold, H., Koch, I., Haberl, M., Deglmann, C. J., Burk, O., Buntefuss, D., Escher, S., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200103000-00002 · Cited by 226
THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS*
WRIGHTON, S. A., SCHUETZ, E. G., THUMMEL, K. E., SHEN, D. D., KORZEKWA, K. R., & WATKINS, P. B. (2000) · Drug Metabolism Reviews · doi:10.1081/dmr-100102338 · Cited by 213
HASHIMOTO, H., TOIDE, K., KITAMURA, R., FUJITA, M., TAGAWA, S., ITOH, S., & KAMATAKI, T. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb18412.x · Cited by 209
The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups
Mancinelli, L. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113183 · Cited by 206
cDNA Cloning and Initial Characterization of CYP3A43, a Novel Human Cytochrome P450
Domanski, T. L., Finta, C., Halpert, J. R., & Zaphiropoulos, P. G. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12850-7 · Cited by 205
An unappreciated role for RNA surveillance
Hillman, R. T., Green, R. E., & Brenner, S. E. (2004) · Genome Biology · doi:10.1186/gb-2004-5-2-r8 · Cited by 193
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
Wadelius, M., Sörlin, K., Wallerman, O., Karlsson, J., Yue, Q.-Y., Magnusson, P. K. E., Wadelius, C., & Melhus, H. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500220 · Cited by 191
Paris, P. L., Kupelian, P. A., Hall, J., et al. (1999) · PubMed · Cited by 189
Benet, L., Cummins, C., & Wu, C. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489389 · Cited by 188
Schuetz, E. G., Schuetz, J. D., Strom, S. C., Thompson, M. T., Fisher, R. A., Molowa, D. T., Li, D., & Guzelian, P. S. (1993) · Hepatology · doi:10.1002/hep.1840180535 · Cited by 184
Xie, H.-G., Stein, C. M., Kim, R. B., Wilkinson, G. R., Flockhart, D. A., & Wood, A. J. J. (1999) · Pharmacogenetics · doi:10.1097/00008571-199910000-00001 · Cited by 181
Self-citationFukuen, S., Fukuda, T., Maune, H., Ikenaga, Y., Yamamoto, I., Inaba, T., & Azuma, J. (2002) · Pharmacogenetics · doi:10.1097/00008571-200206000-00009 · Cited by 179
Cloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43
Westlind, A., Malmebo, S., Johansson, I., Otter, C., Andersson, T. B., Ingelman-Sundberg, M., & Oscarson, M. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4505 · Cited by 178
The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons
Finta, C., & Zaphiropoulos, P. G. (2000) · Gene · doi:10.1016/s0378-1119(00)00470-4 · Cited by 170
Lee, S.-J., Usmani, K. A., Chanas, B., Ghanayem, B., Xi, T., Hodgson, E., Mohrenweiser, H. W., & Goldstein, J. A. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00004 · Cited by 167
Cummins, C. L., Wu, C., & Benet, L. Z. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.128388 · Cited by 166
Expression of cytochrome P450 3A in amphibian, rat, and human kidney
Schuetz, E. G., Schuetz, J. D., Grogan, W. M., Náray‐Fejes‐Tóth, A., Fejes‐Tóth, G., Raucy, J. L., Guzelian, P. S., Gionela, K., & Watlington, C. O. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90159-t · Cited by 162
In vitro and pharmacophore insights into CYP3A enzymes
Ekins, S., Stresser, D. M., & Williams, J. A. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00049-x · Cited by 161
Kittles, R. A., Chen, W., Panguluri, R. K., Ahaghotu, C., Jackson, A., Adebamowo, C. A., Griffin, R., Williams, T., Ukoli, F., Adams-Campbell, L., et al. (2002) · Human Genetics · doi:10.1007/s00439-002-0731-5 · Cited by 160
Expression and Localization of CYP3A4 and CYP3A5 in Human Lung
Anttila, S. L., Hukkanen, J., Hakkola, J., Stjernvall, T., Beaune, P. H., Edwards, R. J., Boobis, A. R., Pelkonen, O., & Raunio, H. (1997) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.16.3.9070608 · Cited by 154
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration
Lin, Y. S., Lockwood, G. F., Graham, M. A., Brian, W. R., Loi, C., Dobrinska, M. R., Shen, D. D., Watkins, P. B., Wilkinson, G. R., Kharasch, E. D., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00006 · Cited by 147
Self-citationPharmacokinetics of Midazolam and 1′-Hydroxymidazolam in Chinese with Different CYP3A5 Genotypes
Shih, P.-S., & Huang, J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1491 · Cited by 146
CYP3A5genotype predicts renal CYP3A activity and blood pressure in healthy adults
Givens, R. C., Lin, Y. S., Dowling, A. L. S., et al. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00322.2003 · Cited by 132
Human population structure and genetic association studies
Ziv, E., & Burchard, E. G. (2003) · Pharmacogenomics · doi:10.1517/phgs.4.4.431.22758 · Cited by 119
Kadlubar, F. F., Berkowitz, G. S., Delongchamp, R. R., Wang, C., Green, B. L., Tang, G. Y., Lamba, J. K., Schuetz, E. G., & Wolff, M. S. (2003) · PubMed · Cited by 116
CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.
Plummer, S. J., Conti, D. V., Paris, P. L., Curran, A. P., Casey, G., & Witte, J. S. (2003) · PubMed · Cited by 109
Paulussen, A. D. C., Lavrijsen, K., Bohets, H., Hendrickx, J., Verhasselt, P., Luyten, W. H. M. L., Konings, F., & Armstrong, M. (2000) · Pharmacogenetics · doi:10.1097/00008571-200007000-00005 · Cited by 101
The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose
Dally, H., Edler, L., ger, B. J., Schmezer, P., Spiegelhalder, B., Dienemann, H., Drings, P., Schulz, V., Kayser, K., Bartsch, H., et al. (2003) · Pharmacogenetics · doi:10.1097/00008571-200310000-00004 · Cited by 100
Blanco, J. G., Edick, M. J., Hancock, M. L., Winick, N. J., Dervieux, T., Amylon, M. D., Bash, R. O., Behm, F. G., Camitta, B. M., Pui, C., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200211000-00004 · Cited by 100
Regulation of CYP3A5 by Glucocorticoids and Cigarette Smoke in Human Lung-Derived Cells
Hukkanen, J., Väisänen, T., Lassila, A., Piipari, R., Anttila, S. L., Pelkonen, O., Raunio, H., & Hakkola, J. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038208 · Cited by 95
Mdr1 Limits CYP3A Metabolism in Vivo
Lan, L.-B., Dalton, J. T., & Schuetz, E. G. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.4.863 · Cited by 90
CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations
Balram, C., Zhou, Q. S., Cheung, Y. B., & Lee, E. J. D. (2003) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-003-0594-2 · Cited by 87
Meta-analysis: A method for synthesizing research*
D’Agostino, R. B., & WEINTRAUB, M. I. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90016-0 · Cited by 84
CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia
Aplenc, R., Glatfelter, W., Han, P. P., Rappaport, E. F., La, M., Cnaan, A., Blackwood, M. A., Lange, B. J., & Rebbeck, T. R. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04430.x · Cited by 82
Detection of a CYP3A5 Allelic Variant: A Candidate for the Polymorphic Expression of the Protein?
Jounaïdi, Y., Hyrailles, V., Gervot, L., & Maurel, P. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.0618 · Cited by 80
CYP3A5 phenotype‐genotype correlations in a British population
King, B. P., Leathart, J. B. S., Mutch, E., Williams, F. M., & Daly, A. K. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01798.x · Cited by 75
Kivist, K. T., Griese, E., Fritz, P., Linder, A., Hakkola, J., Raunio, H., Beaune, P. H., & Kroemer, H. (1996) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00168759 · Cited by 74
Detection of cytochrome P450 mRNA transcripts in prostate samples by RT‐PCR
Finnström, N., Bjelfman, C., Söderström, T. G., Smith, G. C., Egevad, L., Norlén, B. J., Wolf, C. R., & Rane, A. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00893.x · Cited by 74
Wu, C., & Benet, L. Z. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1292 · Cited by 63
Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations
Rogan, P. K., Svojanovsky, S. R., & Leeder, J. S. (2003) · Pharmacogenetics · doi:10.1097/00008571-200304000-00005 · Cited by 61
mRNA surveillance in mammalian cells: The relationship between introns and translation termination
Sun, X., & Maquat, L. E. (2000) · RNA · doi:10.1017/s1355838200991660 · Cited by 56
Sequence of the 5′-Flanking Region of CYP3A5: Comparative Analysis with CYP3A4 and CYP3A7
Jounaïdi, Y., Guzelian, P. S., Maurel, P., & Vilarem, M. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2870 · Cited by 54
Lin, Y., Anderson, G. D., Kantor, E. D., Ojemann, L. M., & Wilensky, A. J. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008182 · Cited by 54
Haga, S. B., & Venter, J. C. (2003) · Science · doi:10.1126/science.1087004 · Cited by 50
CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers
Fukuda, T., Onishi, S., Fukuen, S., Ikenaga, Y., Ohno, M., Hoshino, K., Matsumoto, K., Maihara, A., Momiyama, K., Ito, T., et al. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500218 · Cited by 48
A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5?
Williams, J. A., Cook, J., & Hurst, S. I. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.12.1526 · Cited by 47
CYP3A5 is the major cytochrome P450 3A expressed in human colon and colonic cell lines
Gervot, L., Carrière, V., Costet, P., Cugnenc, P., Berger, A., Beaune, P. H., & de Waziers, I. (1996) · Environmental Toxicology and Pharmacology · doi:10.1016/s1382-6689(96)00075-0 · Cited by 45
Race, Distributive Justice and the Promise of Pharmacogenomics: Ethical Considerations
Lee, S. S. (2003) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200303060-00005 · Cited by 45
Yamakoshi, Y., Kishimoto, T., Sugimura, K., & Kawashima, H. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0960 · Cited by 40
Meisel, C., Roots, I., Cascorbi, I., Brinkmann, U., & Brockmöller, J. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.126 · Cited by 39
Cyclosporine A: Clinical Experience and Therapeutic Drug Monitoring
Lindholm, A. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199512000-00015 · Cited by 35
The Pharmacogenetics of Immunosuppression for Organ Transplantation
Fredericks, S., Holt, D. W., & MacPhee, I. A. M. (2003) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200303050-00001 · Cited by 28
Pharmacogenomics and the (ir)relevance of race
Rothstein, M. A., & Epps, P. G. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500029 · Cited by 19
CYP3A5*1is an Inhibitory Factor for Lung Cancer in Taiwanese
Yeh, K., Chen, J., Chen, C., Wang, Y., Lee, T., & Chang, J. (2003) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/s1607-551x(09)70425-5 · Cited by 18
Cited by
Resistance to clopidogrel: A review of the evidence
Nguyen, T. A., Diodati, J. G., & Pharand, C. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.034 · Cited by 520
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing
Thervet, E., Loriot, M. A., Barbier, S., Buchler, M., Ficheux, M., Choukroun, G., Toupance, O., Touchard, G., Alberti, C., Le Pogamp, P., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.17 · Cited by 369
Cytochrome P450 variations in different ethnic populations
McGraw, J., & Waller, D. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.657626 · Cited by 286
Metadata
- Authors
- Xie, H.-G., Wood, A. J., Kim, R. B., Stein, C. M., & Wilkinson, G. R.
- Venue
- Pharmacogenomics
- Publisher
- Informa UK Limited
- Published
- 2004-04
- Volume
- 5
- Issue
- 3
- Pages
- 243-272
- ISSN
- 1462-2416 (ISSN-L)
- 1744-8042
- OpenAlex
- W2164539379
- Cited by
- 302
- References
- 118
- FWCI
- 20.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.